Periodontal diagnostics.
Periodontitis affects a subset of the population and our current thinking is that progression of periodontal disease may be either continuous or cyclical (burst hypothesis). These features make screening and diagnostic tools desirable in the management of this disease. Although many potential markers exist, several difficulties hamper our ability to declare them diagnostic tests with proven utility. The 'gold standard' for active periodontal disease is not available and inflammation due to gingivally confined lesions (gingivitis) and periodontal inflammation which results in attachment loss is a potential confounder of any test based on assessing the host response elements of the disease. The current absence of proof for the progression of periodontal disease i.e., whether or not the burst hypothesis is correct, is a further problem. Although much is written about the need for markers of current or future disease which will prevent us from overtreating pockets, the time, effort and cost involved in testing these sites has to be balanced against the relative ease and speed of routine therapy such as root planing. In addition, we are still some way from the development and validation of reliable host or microbial testing methods. In terms of screening tests for diseases such as the early-onset forms of periodontitis, the research and development on diagnostic tools involving genetic polymorphisms, specific genes, systemic antibodies or leucocyte cell surface markers of the patients, may become a clinical reality in time. One could envisage chairside tests using blood from thumb pricks being capable of determining a young individual's risk of developing disease at a later age, and thus the need for a timely prevention programme. Before applying any test we should reconsider what treatment planning effects a positive or negative result will have, and any test which does not influence the treatment plan is redundant. Whether periodontal diagnostic tests will be developed which will indicate to the clinician the need for various treatment regimes other than root planing, is still an open question. For example, in the future, a test of specific antibody levels in patients prior to treatment might indicate their likely response to therapy and thus the need for additional therapeutic agents such as antibiotics. Periodontal diagnostic tests are still at an early stage of development and much work remains to be performed to fully validate their utility such that they become an important and cost effective aspect of clinical treatment planning, screening or patient monitoring.
Kinane
D F
DF
Glasgow Dental Hospital and School, Scotland.
D010520:Aggressive Periodontitis / Q000175:diagnosis; D015415:Biomarkers / Q000032:analysis; D002985:Clinical Protocols; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D005821:Genetic Techniques; D005891:Gingivitis / Q000175:diagnosis; D006801:Humans; D008403:Mass Screening; D016017:Odds Ratio; D010347:Patient Care Planning; D017622:Periodontal Attachment Loss / Q000175:diagnosis / Q000628:therapy; D010510:Periodontal Diseases / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D010514:Periodontal Pocket / Q000175:diagnosis / Q000628:therapy; D010518:Periodontitis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity
D015415:Biomarkers